Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Rosetta Genomics Ltd. (ROSG)
25th Annual ROTH Conference
March 19, 2013 7:30 p.m. ET
Ken Berlin – President and CEO
Yale Jen – ROTH Capital
Yale Jen – ROTH Capital
» Rosetta Genomics Ltd. Q2 2008 Earnings Call Transcript
» TearLab's CEO Discusses Q4 2012 Results - Earnings Call Transcript
And Rosetta has this microRNA for diagnostic for cancer, has already get quite a few milestones accomplished. Ken certainly illuminate all those, so it's all yours.
Thank you. So, 13 years ago this month, we opened our doors for business, firmly planting our flag in the area of junk. That junk are small, non-coding RNA sequences, that are now called microRNAs. And as it turns out, microRNAs have actually revolutionized our understanding of gene expression and cell biology. And we've been at the forefront of that revolution.
We have discovered hundreds of microRNAs when they were thought to believe -- when it was believed that they were thought that there were only 100 microRNAs. We have the leading patent [slate] in the field. We have led studies related to our platform that have resulted in over 40 peer reviewed publications. And we've launched already six assays in the space, by far the most in the space.
And while these accomplishments have been significant, they've been largely in the technical and scientific arena. So now as we mark our 13-year anniversary, we believe we're poised to make some progress in the commercial front. So for the next 25 minutes or so, I'll take you through the commercial opportunities that we're going after and how we plan to seize them.
Here's our disclaimer regarding forward-looking statements and our duty to update.
So, really some highlights, we like the space that we're in. We think molecular diagnostics has been and will continue to be a high-growth space. And just a word on our business model, because it's different from some others, we're a sole source laboratory, so we develop laboratory tests and all the samples come into our lab, and we bill directly to patients. And we believe that diagnostics space on genetic information of patients and their disease will continue to be important and going with the grain of healthcare, not the one-size-fits-all healthcare, but really more and more personalized healthcare.
Our edge in the space is, as Yale mentioned, microRNAs. MicroRNAs are these small non-coding RNA sequences which are extremely sensitive biomarkers. And as I mentioned, we have a leading patent position in the space. We also have launched products on the market today, I'll take you through those products and how we plan to optimize their revenue potential. But some of the key highlights from last year, including getting Medicare coverage for our lead product, also entering into a co-marketing arrangement with a party that has 30 sales reps out there calling on the docs that we need to call on. And we've also launched another assay called miRview kidney which I'll talk about in a little bit.
We also have a nice cash runway. We raised a fair amount of capital last year, so we have at least 24 months of cash to run our operations. And we have a management team that's been there and executed in similar spaces, which I'll talk about.
So, on our management team, we have Chairman of the Board, Brian Markison. Brian has a ton of commercial experience. He's led two companies through very nice exits, King Pharmaceuticals who was sold to Pfizer for close to $4 billion, and Fougera Pharmaceuticals, a derm business, which was sold to Novartis for north of $1 billion. Brian also brings some relevant oncology commercial experience, which is very helpful.
I came to Rosetta back in November of 2009 directly from Johnson & Johnson. At Johnson & Johnson, I ran their cancer diagnostics business and faced very similar challenges as the ones that we face here at Rosetta today, namely we launched some novel technologies in that space at J&J, and when I joined, the company was struggling, it needed traction in that space, and we're really able to get that up the revenue curve. So we're looking to do the same thing here.
I have a CFO that we brought in recently from Israel, Ron Kalfus, who actually did his training here in the US. He's been a great partner for me. We also recently brought on board a new Chief Medical Officer who brings over 30 years of medical genetics experience, a new Chief Scientific Officer, Dganit Bar, who brings a wealth of experience relevant to the things that we're working on, and new Head of Corporate Development, Guy Malchi, who's helping us on a number of our business development initiatives.
So a little bit more about microRNAs, they are truly acknowledged as outstanding biomarkers. They play a master gene regulatory role in cell biology by how they regular messenger RNAs and determine what proteins those messenger RNAs are going to produce, and that has a major impact on the cell biology. They're very tissue specific. You see that borne out in the accuracy data that you'll see associated with the tests that we've launched. And they're implicated in most major diseases and they're very easy to work with because they're extremely stable.
In terms of our patent position, we have access to over half of the known microRNAs. We just had another patent issue or allowed that we announced earlier this week, so we now have 29 patents that are either issue or been allowed. We have 41 patent applications. And we have, exclusively to ourselves, about one-third of the publicly-known microRNAs an access to close to three-quarters of the known microRNAs.